Sarah Waliany

1.4k total citations
34 papers, 857 citations indexed

About

Sarah Waliany is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sarah Waliany has authored 34 papers receiving a total of 857 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Sarah Waliany's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (8 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Sarah Waliany is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (8 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Sarah Waliany collaborates with scholars based in United States, India and France. Sarah Waliany's co-authors include Ronald Witteles, Han Zhu, Sean M. Wu, Joel W. Neal, Patricia K. Nguyen, Mark M. Davis, Holden T. Maecker, Sandy Srinivas, Joanne Mortimer and Heather A. Wakelee and has published in prestigious journals such as Circulation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Sarah Waliany

33 papers receiving 838 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Waliany United States 14 445 209 177 169 122 34 857
Ofra Barnett‐Griness Israel 20 288 0.6× 351 1.7× 104 0.6× 228 1.3× 56 0.5× 53 1.3k
Judith Löffler‐Ragg Austria 21 250 0.6× 80 0.4× 400 2.3× 285 1.7× 241 2.0× 71 1.2k
Darla Liles United States 16 160 0.4× 292 1.4× 105 0.6× 210 1.2× 73 0.6× 75 1.6k
Sophie Fédrizzi France 13 358 0.8× 70 0.3× 172 1.0× 76 0.4× 28 0.2× 49 727
Fady Hannah‐Shmouni United States 18 132 0.3× 124 0.6× 62 0.4× 395 2.3× 107 0.9× 85 1.2k
Iris Navarro‐Millán United States 17 77 0.2× 143 0.7× 68 0.4× 165 1.0× 75 0.6× 59 1.3k
Basile Chrétien France 11 530 1.2× 53 0.3× 207 1.2× 111 0.7× 21 0.2× 48 921
Qiang Wen China 21 275 0.6× 62 0.3× 275 1.6× 258 1.5× 36 0.3× 72 1.0k
Aditya Mandawat United States 17 114 0.3× 256 1.2× 126 0.7× 423 2.5× 18 0.1× 24 1.1k
Ruonan Yang China 8 270 0.6× 56 0.3× 98 0.6× 51 0.3× 46 0.4× 19 528

Countries citing papers authored by Sarah Waliany

Since Specialization
Citations

This map shows the geographic impact of Sarah Waliany's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Waliany with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Waliany more than expected).

Fields of papers citing papers by Sarah Waliany

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Waliany. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Waliany. The network helps show where Sarah Waliany may publish in the future.

Co-authorship network of co-authors of Sarah Waliany

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Waliany. A scholar is included among the top collaborators of Sarah Waliany based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Waliany. Sarah Waliany is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Yin, Abraham Bayer, Daniel Lee, et al.. (2025). Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis. Circulation Research. 136(5). 473–490. 3 indexed citations
2.
Waliany, Sarah, W. Marston Linehan, & Justin F. Gainor. (2025). Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer. Trends in cancer. 11(3). 245–257. 3 indexed citations
3.
Waliany, Sarah, B.Y. Yeap, Jennifer Peterson, et al.. (2025). Adverse events associated with sequential immune checkpoint inhibitor and alectinib in patients with ALK-rearranged advanced non-small-cell lung cancer. ESMO Open. 10(10). 105842–105842. 1 indexed citations
4.
Waliany, Sarah, Yin P. Hung, Marzia Capelletti, et al.. (2025). Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies. Clinical Lung Cancer. 26(5). 354–363.e5. 2 indexed citations
5.
6.
Leong, Darryl P., Sarah Waliany, Husam Abdel‐Qadir, et al.. (2024). Cardiovascular Considerations During Cancer Therapy. JACC CardioOncology. 6(6). 815–834. 7 indexed citations
7.
Waliany, Sarah, Andrew Do, Aimin Liu, et al.. (2024). P1.12B.02 Mechanisms of Resistance to First-Line vs Later-Line Alectinib in ALK Fusion-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 19(10). S199–S200. 2 indexed citations
8.
Waliany, Sarah, Yin P. Hung, Andrew Do, et al.. (2024). PP01.69 Atypical Lung Carcinoids with EML4-ALK Fusion and Responses to ALK Inhibitors. Journal of Thoracic Oncology. 19(7). e32–e33.
9.
Waliany, Sarah, Jennifer L. Caswell‐Jin, Fauzia Riaz, et al.. (2023). Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer. JACC CardioOncology. 5(1). 85–98. 14 indexed citations
10.
Waliany, Sarah, Heather A. Wakelee, Kavitha Ramchandran, et al.. (2022). Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical Lung Cancer. 23(6). 498–509. 4 indexed citations
11.
Zhu, Han, Francisco X. Galdos, Daniel Lee, et al.. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis. Circulation. 146(4). 316–335. 103 indexed citations
12.
Waliany, Sarah, Han Zhu, Heather A. Wakelee, et al.. (2021). Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. Journal of Thoracic Oncology. 16(12). 2029–2039. 59 indexed citations
13.
Waliany, Sarah, Joel W. Neal, Sunil Reddy, et al.. (2021). Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors. JACC CardioOncology. 3(1). 137–139. 77 indexed citations
14.
Waliany, Sarah, Kristin L. Sainani, Lesley S. Park, et al.. (2019). Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor. JACC CardioOncology. 1(1). 24–36. 44 indexed citations
15.
Waliany, Sarah, et al.. (2019). Preclinical curriculum of prospective case-based teaching with faculty- and student-blinded approach. BMC Medical Education. 19(1). 31–31. 17 indexed citations
16.
Mortimer, Joanne, Sarah Waliany, Christina M. Dieli‐Conwright, et al.. (2017). Objective physical and mental markers of self‐reported fatigue in women undergoing (neo)adjuvant chemotherapy for early‐stage breast cancer. Cancer. 123(10). 1810–1816. 13 indexed citations
17.
Waliany, Sarah. (2016). Health Professionals with Disabilities: Motivating Inclusiveness and Representation. The AMA Journal of Ethic. 18(10). 971–974. 5 indexed citations
18.
Bergerot, Cristiane Decat, et al.. (2013). Course of distress, anxiety, and depression in hematological cancer patients: Association between gender and grade of neoplasm. Palliative & Supportive Care. 13(2). 115–123. 53 indexed citations
19.
Pal, Sumanta K., Rebecca A. Nelson, Susan Onami, et al.. (2012). Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer. BMC Cancer. 12(1). 435–435. 15 indexed citations
20.
Gu, Long, Sarah Waliany, & Susan E. Kane. (2009). Darpp-32 and Its Truncated Variant t-Darpp Have Antagonistic Effects on Breast Cancer Cell Growth and Herceptin Resistance. PLoS ONE. 4(7). e6220–e6220. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ofra Barnett‐Griness Breakdown of academic impact, for papers by Judith Löffler‐Ragg Breakdown of academic impact, for papers by Darla Liles Breakdown of academic impact, for papers by Sophie Fédrizzi Breakdown of academic impact, for papers by Fady Hannah‐Shmouni Breakdown of academic impact, for papers by Iris Navarro‐Millán Breakdown of academic impact, for papers by Basile Chrétien Breakdown of academic impact, for papers by Qiang Wen Breakdown of academic impact, for papers by Aditya Mandawat Breakdown of academic impact, for papers by Ruonan Yang
Rankless by CCL
2026